Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Costs | 27 | 2022 | 1195 | 5.510 |
Why?
|
Drug Industry | 17 | 2024 | 791 | 3.050 |
Why?
|
Prescription Drugs | 11 | 2022 | 635 | 2.760 |
Why?
|
Lung Neoplasms | 46 | 2024 | 13586 | 2.650 |
Why?
|
Medicare | 53 | 2023 | 6809 | 2.600 |
Why?
|
Medical Oncology | 17 | 2021 | 2346 | 2.130 |
Why?
|
Neoplasms | 54 | 2024 | 22371 | 1.890 |
Why?
|
Ureteroscopy | 3 | 2021 | 140 | 1.840 |
Why?
|
Reimbursement Mechanisms | 7 | 2018 | 670 | 1.830 |
Why?
|
Cost Control | 7 | 2019 | 627 | 1.510 |
Why?
|
Antineoplastic Agents | 25 | 2024 | 13676 | 1.500 |
Why?
|
Early Detection of Cancer | 15 | 2024 | 3239 | 1.480 |
Why?
|
Mass Screening | 22 | 2024 | 5458 | 1.390 |
Why?
|
Drug Approval | 6 | 2022 | 821 | 1.380 |
Why?
|
Prescription Fees | 4 | 2019 | 153 | 1.310 |
Why?
|
United States | 109 | 2024 | 73039 | 1.300 |
Why?
|
Tomography, X-Ray Computed | 26 | 2022 | 20760 | 1.260 |
Why?
|
Ureteral Calculi | 2 | 2020 | 111 | 1.200 |
Why?
|
Economics, Pharmaceutical | 2 | 2018 | 88 | 1.180 |
Why?
|
Cancer Care Facilities | 9 | 2024 | 427 | 1.160 |
Why?
|
Health Care Costs | 8 | 2020 | 3239 | 1.000 |
Why?
|
Stents | 3 | 2021 | 3195 | 0.880 |
Why?
|
Insurance Coverage | 8 | 2018 | 1946 | 0.840 |
Why?
|
Physicians' Offices | 3 | 2018 | 60 | 0.820 |
Why?
|
Costs and Cost Analysis | 5 | 2020 | 1667 | 0.810 |
Why?
|
Conflict of Interest | 4 | 2024 | 556 | 0.800 |
Why?
|
Health Expenditures | 11 | 2020 | 2389 | 0.800 |
Why?
|
Developed Countries | 3 | 2022 | 451 | 0.790 |
Why?
|
SEER Program | 20 | 2021 | 1444 | 0.780 |
Why?
|
Cost-Benefit Analysis | 10 | 2018 | 5536 | 0.770 |
Why?
|
Clinical Trials as Topic | 7 | 2024 | 8054 | 0.750 |
Why?
|
Peer Review, Research | 2 | 2016 | 344 | 0.730 |
Why?
|
Radiography, Thoracic | 6 | 2013 | 1321 | 0.720 |
Why?
|
Patents as Topic | 2 | 2020 | 111 | 0.710 |
Why?
|
Financing, Government | 2 | 2018 | 473 | 0.700 |
Why?
|
Humans | 194 | 2024 | 768166 | 0.670 |
Why?
|
Smoking | 14 | 2015 | 9092 | 0.670 |
Why?
|
Urolithiasis | 1 | 2021 | 123 | 0.650 |
Why?
|
Preventive Health Services | 2 | 2019 | 570 | 0.640 |
Why?
|
Developing Countries | 2 | 2022 | 2910 | 0.630 |
Why?
|
Guideline Adherence | 6 | 2024 | 2235 | 0.630 |
Why?
|
Government Regulation | 2 | 2020 | 525 | 0.620 |
Why?
|
Drugs, Generic | 6 | 2022 | 455 | 0.610 |
Why?
|
Occupational Health Services | 1 | 2019 | 149 | 0.610 |
Why?
|
Wolves | 1 | 2018 | 10 | 0.610 |
Why?
|
Cost Savings | 6 | 2020 | 904 | 0.600 |
Why?
|
Negotiating | 1 | 2019 | 152 | 0.600 |
Why?
|
Neoplasm Staging | 15 | 2024 | 11244 | 0.600 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2018 | 348 | 0.580 |
Why?
|
Legislation, Drug | 1 | 2020 | 216 | 0.580 |
Why?
|
Ureter | 1 | 2020 | 364 | 0.580 |
Why?
|
Medicare Part D | 2 | 2019 | 355 | 0.560 |
Why?
|
Hospitals | 9 | 2019 | 3886 | 0.560 |
Why?
|
Practice Guidelines as Topic | 10 | 2020 | 7454 | 0.560 |
Why?
|
Pharmacies | 1 | 2019 | 171 | 0.550 |
Why?
|
State Health Plans | 1 | 2018 | 220 | 0.540 |
Why?
|
Insurance, Health | 6 | 2019 | 2517 | 0.540 |
Why?
|
Quality of Health Care | 10 | 2018 | 4310 | 0.540 |
Why?
|
Episode of Care | 3 | 2013 | 127 | 0.530 |
Why?
|
Drug Packaging | 1 | 2016 | 44 | 0.530 |
Why?
|
Physicians, Women | 2 | 2019 | 517 | 0.510 |
Why?
|
Intensive Care Units | 5 | 2017 | 3800 | 0.510 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2016 | 388 | 0.500 |
Why?
|
Administrative Personnel | 1 | 2015 | 185 | 0.460 |
Why?
|
Patient Advocacy | 1 | 2016 | 362 | 0.460 |
Why?
|
Health Services Research | 7 | 2016 | 1815 | 0.460 |
Why?
|
Physical Examination | 2 | 2019 | 1263 | 0.450 |
Why?
|
Advisory Committees | 2 | 2019 | 797 | 0.450 |
Why?
|
Physicians | 7 | 2022 | 4598 | 0.450 |
Why?
|
Pharmaceutical Preparations | 2 | 2022 | 1088 | 0.440 |
Why?
|
Continuity of Patient Care | 3 | 2012 | 1078 | 0.440 |
Why?
|
Prostatectomy | 6 | 2020 | 1786 | 0.430 |
Why?
|
Fee-for-Service Plans | 8 | 2022 | 713 | 0.420 |
Why?
|
Cost Sharing | 3 | 2017 | 409 | 0.420 |
Why?
|
Catheters, Indwelling | 1 | 2015 | 436 | 0.410 |
Why?
|
Survivors | 3 | 2017 | 2381 | 0.410 |
Why?
|
Aged | 75 | 2024 | 171504 | 0.400 |
Why?
|
United States Food and Drug Administration | 5 | 2022 | 1673 | 0.400 |
Why?
|
Mass Chest X-Ray | 2 | 2011 | 18 | 0.400 |
Why?
|
Fees and Charges | 1 | 2013 | 189 | 0.400 |
Why?
|
Catheter-Related Infections | 2 | 2015 | 275 | 0.390 |
Why?
|
Rehabilitation Centers | 1 | 2013 | 249 | 0.390 |
Why?
|
Health Services Misuse | 1 | 2013 | 246 | 0.380 |
Why?
|
Aftercare | 2 | 2017 | 916 | 0.370 |
Why?
|
Centralized Hospital Services | 1 | 2010 | 15 | 0.370 |
Why?
|
Albumins | 1 | 2014 | 577 | 0.370 |
Why?
|
Off-Label Use | 1 | 2013 | 185 | 0.370 |
Why?
|
Hematologic Neoplasms | 2 | 2019 | 1907 | 0.370 |
Why?
|
Publishing | 1 | 2018 | 837 | 0.370 |
Why?
|
Government Programs | 1 | 2013 | 278 | 0.360 |
Why?
|
Health Policy | 10 | 2021 | 2698 | 0.360 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2018 | 1375 | 0.360 |
Why?
|
Oncology Service, Hospital | 1 | 2010 | 56 | 0.360 |
Why?
|
Publication Bias | 1 | 2011 | 158 | 0.360 |
Why?
|
Critical Illness | 4 | 2017 | 2756 | 0.350 |
Why?
|
T-Lymphocytes | 2 | 2018 | 10266 | 0.350 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2020 | 5432 | 0.350 |
Why?
|
Physicians, Family | 4 | 2010 | 349 | 0.350 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2016 | 798 | 0.340 |
Why?
|
Prostatic Neoplasms | 11 | 2022 | 11101 | 0.340 |
Why?
|
Decision Making, Organizational | 1 | 2010 | 136 | 0.340 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2010 | 155 | 0.340 |
Why?
|
Delivery of Health Care | 5 | 2015 | 5367 | 0.330 |
Why?
|
Decision Making | 5 | 2018 | 3953 | 0.330 |
Why?
|
Urinary Bladder Neoplasms | 5 | 2024 | 2195 | 0.320 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2568 | 0.320 |
Why?
|
Deoxycytidine | 1 | 2014 | 887 | 0.320 |
Why?
|
Cystectomy | 5 | 2024 | 603 | 0.320 |
Why?
|
Guanine | 1 | 2010 | 280 | 0.320 |
Why?
|
Skilled Nursing Facilities | 1 | 2013 | 405 | 0.320 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2010 | 277 | 0.320 |
Why?
|
Glutamates | 1 | 2010 | 385 | 0.320 |
Why?
|
Recombinant Fusion Proteins | 1 | 2017 | 3740 | 0.320 |
Why?
|
Female | 81 | 2024 | 397192 | 0.320 |
Why?
|
Germany | 4 | 2024 | 883 | 0.310 |
Why?
|
Reoperation | 4 | 2018 | 4329 | 0.310 |
Why?
|
Models, Statistical | 4 | 2013 | 5107 | 0.310 |
Why?
|
Europe | 3 | 2024 | 3436 | 0.310 |
Why?
|
Outpatients | 1 | 2017 | 1600 | 0.310 |
Why?
|
Aged, 80 and over | 35 | 2020 | 59629 | 0.310 |
Why?
|
Hepatitis C | 1 | 2018 | 1595 | 0.300 |
Why?
|
Surgical Procedures, Operative | 2 | 2010 | 1932 | 0.300 |
Why?
|
Male | 74 | 2024 | 364719 | 0.300 |
Why?
|
Sputum | 5 | 2013 | 517 | 0.290 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2024 | 300 | 0.290 |
Why?
|
Breast Neoplasms | 10 | 2020 | 21206 | 0.290 |
Why?
|
Medicaid | 6 | 2018 | 2840 | 0.290 |
Why?
|
Hospital Mortality | 6 | 2020 | 5349 | 0.290 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 11878 | 0.290 |
Why?
|
Colonic Neoplasms | 4 | 2015 | 2541 | 0.280 |
Why?
|
Anthracyclines | 1 | 2009 | 286 | 0.280 |
Why?
|
Gatekeeping | 1 | 2007 | 49 | 0.280 |
Why?
|
Quality Indicators, Health Care | 3 | 2020 | 1805 | 0.280 |
Why?
|
United States Agency for Healthcare Research and Quality | 1 | 2007 | 86 | 0.280 |
Why?
|
Hospitalization | 7 | 2017 | 10840 | 0.280 |
Why?
|
Family Practice | 2 | 2010 | 509 | 0.270 |
Why?
|
Commerce | 4 | 2018 | 612 | 0.270 |
Why?
|
Health Care Sector | 2 | 2021 | 196 | 0.270 |
Why?
|
New York City | 6 | 2017 | 737 | 0.270 |
Why?
|
Databases, Factual | 5 | 2019 | 8080 | 0.270 |
Why?
|
Health Services Accessibility | 7 | 2013 | 5520 | 0.270 |
Why?
|
Hospital Administration | 1 | 2010 | 351 | 0.260 |
Why?
|
Paclitaxel | 1 | 2014 | 1733 | 0.260 |
Why?
|
Patient Care Planning | 1 | 2012 | 905 | 0.260 |
Why?
|
Radiotherapy, High-Energy | 1 | 2006 | 228 | 0.260 |
Why?
|
Particle Accelerators | 1 | 2006 | 173 | 0.260 |
Why?
|
Insurance Claim Review | 5 | 2020 | 744 | 0.260 |
Why?
|
Taxoids | 1 | 2009 | 667 | 0.260 |
Why?
|
Rewarming | 1 | 2005 | 64 | 0.250 |
Why?
|
Health Services Needs and Demand | 1 | 2013 | 1406 | 0.250 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1465 | 0.250 |
Why?
|
Efficiency, Organizational | 1 | 2010 | 697 | 0.250 |
Why?
|
Comparative Effectiveness Research | 1 | 2010 | 714 | 0.240 |
Why?
|
Hormone Replacement Therapy | 1 | 2010 | 757 | 0.240 |
Why?
|
Hospital Costs | 4 | 2017 | 957 | 0.240 |
Why?
|
Neoplasms, Second Primary | 1 | 2012 | 1061 | 0.230 |
Why?
|
Insurance Benefits | 1 | 2006 | 185 | 0.230 |
Why?
|
Physicians, Primary Care | 1 | 2011 | 624 | 0.230 |
Why?
|
Vitamins | 1 | 2012 | 1638 | 0.230 |
Why?
|
Pneumonia, Bacterial | 1 | 2007 | 320 | 0.230 |
Why?
|
Quality of Life | 6 | 2024 | 13490 | 0.230 |
Why?
|
Hypothermia | 1 | 2005 | 189 | 0.230 |
Why?
|
Healthcare Disparities | 2 | 2011 | 3415 | 0.230 |
Why?
|
Papillomavirus Vaccines | 1 | 2010 | 497 | 0.220 |
Why?
|
Ovarian Neoplasms | 2 | 2020 | 4916 | 0.220 |
Why?
|
Urinary Diversion | 1 | 2024 | 134 | 0.220 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2024 | 3556 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2012 | 10399 | 0.220 |
Why?
|
Ambulatory Care | 1 | 2014 | 2783 | 0.220 |
Why?
|
National Health Programs | 1 | 2007 | 442 | 0.220 |
Why?
|
Adenocarcinoma | 4 | 2017 | 6395 | 0.210 |
Why?
|
Medical Record Linkage | 4 | 2019 | 286 | 0.210 |
Why?
|
Antibodies, Monoclonal | 3 | 2024 | 9263 | 0.210 |
Why?
|
Socioeconomic Factors | 8 | 2017 | 7852 | 0.210 |
Why?
|
Asia | 1 | 2024 | 629 | 0.200 |
Why?
|
Evidence-Based Medicine | 6 | 2014 | 3706 | 0.200 |
Why?
|
Coronary Artery Bypass | 2 | 2009 | 2191 | 0.200 |
Why?
|
Immunotherapy | 1 | 2018 | 4755 | 0.200 |
Why?
|
Postoperative Complications | 11 | 2020 | 15832 | 0.200 |
Why?
|
Comorbidity | 6 | 2016 | 10590 | 0.200 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3533 | 0.200 |
Why?
|
Palliative Care | 2 | 2016 | 3643 | 0.200 |
Why?
|
Treatment Outcome | 18 | 2020 | 65371 | 0.190 |
Why?
|
Vancomycin Resistance | 1 | 2002 | 125 | 0.190 |
Why?
|
Reimbursement, Incentive | 1 | 2007 | 541 | 0.190 |
Why?
|
Pleural Cavity | 2 | 2015 | 27 | 0.190 |
Why?
|
Arthroplasty, Replacement, Knee | 2 | 2009 | 1389 | 0.190 |
Why?
|
Urology | 2 | 2021 | 384 | 0.190 |
Why?
|
Radiation Oncology | 2 | 2010 | 572 | 0.190 |
Why?
|
Mammography | 2 | 2013 | 2433 | 0.190 |
Why?
|
Postmenopause | 1 | 2010 | 2518 | 0.190 |
Why?
|
Endpoint Determination | 1 | 2024 | 592 | 0.190 |
Why?
|
Middle Aged | 41 | 2024 | 223492 | 0.190 |
Why?
|
Time Factors | 11 | 2024 | 40218 | 0.190 |
Why?
|
Surgery Department, Hospital | 3 | 2010 | 170 | 0.190 |
Why?
|
Enterococcus | 1 | 2002 | 159 | 0.180 |
Why?
|
Licensure | 1 | 2022 | 127 | 0.180 |
Why?
|
Pancreatectomy | 3 | 2017 | 825 | 0.180 |
Why?
|
Risk Adjustment | 3 | 2019 | 599 | 0.180 |
Why?
|
Cross-Sectional Studies | 12 | 2021 | 26379 | 0.180 |
Why?
|
Survival Rate | 10 | 2021 | 12840 | 0.180 |
Why?
|
Health Care Reform | 1 | 2010 | 1256 | 0.180 |
Why?
|
Quality Improvement | 3 | 2020 | 3857 | 0.180 |
Why?
|
Diagnostic Errors | 1 | 2008 | 1281 | 0.180 |
Why?
|
Pneumonectomy | 4 | 2014 | 1156 | 0.180 |
Why?
|
Health Care Surveys | 3 | 2024 | 2434 | 0.180 |
Why?
|
North America | 1 | 2024 | 1289 | 0.180 |
Why?
|
Health Status Indicators | 2 | 2003 | 969 | 0.180 |
Why?
|
Mastectomy, Segmental | 2 | 2016 | 974 | 0.180 |
Why?
|
ROC Curve | 4 | 2023 | 3628 | 0.180 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2024 | 794 | 0.180 |
Why?
|
Patient Discharge | 1 | 2013 | 3479 | 0.170 |
Why?
|
Research Support as Topic | 1 | 2024 | 696 | 0.170 |
Why?
|
Data Collection | 5 | 2011 | 3327 | 0.170 |
Why?
|
Ambulatory Care Facilities | 2 | 2016 | 939 | 0.170 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2002 | 342 | 0.170 |
Why?
|
Risk | 5 | 2013 | 9613 | 0.170 |
Why?
|
Dietary Supplements | 1 | 2012 | 3445 | 0.170 |
Why?
|
Urinary Catheterization | 1 | 2020 | 195 | 0.160 |
Why?
|
Chronic Disease | 2 | 2006 | 9384 | 0.160 |
Why?
|
History, 21st Century | 2 | 2020 | 1573 | 0.160 |
Why?
|
Mammaplasty | 3 | 2015 | 1268 | 0.160 |
Why?
|
Patient Care | 1 | 2004 | 629 | 0.160 |
Why?
|
Marketing | 1 | 2021 | 224 | 0.160 |
Why?
|
Insurance Carriers | 1 | 2020 | 159 | 0.160 |
Why?
|
Fees, Pharmaceutical | 1 | 2018 | 66 | 0.160 |
Why?
|
Africa | 1 | 2021 | 725 | 0.160 |
Why?
|
Cohort Studies | 14 | 2023 | 41754 | 0.160 |
Why?
|
Osteoarthritis, Knee | 1 | 2009 | 1251 | 0.160 |
Why?
|
Retrospective Studies | 20 | 2022 | 81762 | 0.150 |
Why?
|
Patient Preference | 2 | 2018 | 946 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2017 | 9419 | 0.150 |
Why?
|
Marketing of Health Services | 1 | 2019 | 151 | 0.150 |
Why?
|
Urban Population | 1 | 2006 | 2046 | 0.150 |
Why?
|
Subtilisins | 1 | 2018 | 80 | 0.150 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2010 | 2043 | 0.140 |
Why?
|
Vaccination | 1 | 2010 | 3437 | 0.140 |
Why?
|
Clothing | 1 | 2018 | 96 | 0.140 |
Why?
|
Proprotein Convertases | 1 | 2018 | 95 | 0.140 |
Why?
|
Minority Groups | 1 | 2005 | 1216 | 0.140 |
Why?
|
History, 20th Century | 2 | 2020 | 2766 | 0.140 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2565 | 0.140 |
Why?
|
Radiation Dosage | 2 | 2018 | 1967 | 0.140 |
Why?
|
Risk Factors | 15 | 2020 | 74944 | 0.140 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2018 | 392 | 0.130 |
Why?
|
Adult | 23 | 2024 | 223646 | 0.130 |
Why?
|
Poverty | 1 | 2008 | 2720 | 0.130 |
Why?
|
Health Benefit Plans, Employee | 1 | 2019 | 332 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2024 | 975 | 0.130 |
Why?
|
Androgen Antagonists | 3 | 2022 | 1412 | 0.130 |
Why?
|
Predictive Value of Tests | 8 | 2015 | 15454 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2014 | 5446 | 0.130 |
Why?
|
Pancreatic Fistula | 1 | 2017 | 149 | 0.130 |
Why?
|
Hydrothorax | 1 | 2015 | 20 | 0.130 |
Why?
|
Mastectomy, Radical | 1 | 2015 | 19 | 0.130 |
Why?
|
Hemothorax | 1 | 2015 | 58 | 0.130 |
Why?
|
Medicare Part B | 1 | 2016 | 116 | 0.120 |
Why?
|
Inappropriate Prescribing | 1 | 2018 | 212 | 0.120 |
Why?
|
Australia | 1 | 2019 | 1265 | 0.120 |
Why?
|
Sheep | 1 | 2018 | 1451 | 0.120 |
Why?
|
Disclosure | 1 | 2021 | 755 | 0.120 |
Why?
|
Antigens, CD19 | 1 | 2018 | 446 | 0.120 |
Why?
|
European Union | 1 | 2016 | 158 | 0.120 |
Why?
|
Camptothecin | 2 | 2024 | 600 | 0.120 |
Why?
|
Chest Tubes | 1 | 2015 | 153 | 0.120 |
Why?
|
Fee Schedules | 1 | 2015 | 86 | 0.120 |
Why?
|
Prospective Payment System | 1 | 2015 | 134 | 0.120 |
Why?
|
Health Services for the Aged | 2 | 2014 | 264 | 0.120 |
Why?
|
Cause of Death | 2 | 2002 | 3721 | 0.120 |
Why?
|
Somatostatin | 1 | 2017 | 458 | 0.120 |
Why?
|
Bone Density Conservation Agents | 1 | 2022 | 797 | 0.120 |
Why?
|
Consensus | 1 | 2024 | 3212 | 0.120 |
Why?
|
Risk Assessment | 9 | 2020 | 24315 | 0.120 |
Why?
|
Nephrectomy | 1 | 2019 | 930 | 0.120 |
Why?
|
Deductibles and Coinsurance | 2 | 2008 | 315 | 0.120 |
Why?
|
Trust | 1 | 2019 | 532 | 0.110 |
Why?
|
Colorectal Neoplasms | 3 | 2024 | 6974 | 0.110 |
Why?
|
Critical Pathways | 1 | 2018 | 476 | 0.110 |
Why?
|
Eligibility Determination | 1 | 2018 | 421 | 0.110 |
Why?
|
Leukemia | 1 | 2002 | 1519 | 0.110 |
Why?
|
Needs Assessment | 2 | 2013 | 1141 | 0.110 |
Why?
|
Ownership | 1 | 2016 | 338 | 0.110 |
Why?
|
Gastrectomy | 2 | 2017 | 693 | 0.110 |
Why?
|
Quality Control | 1 | 2016 | 836 | 0.110 |
Why?
|
Digestive System Surgical Procedures | 3 | 2003 | 583 | 0.110 |
Why?
|
Prospective Studies | 7 | 2024 | 54926 | 0.110 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2014 | 1188 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8542 | 0.110 |
Why?
|
Lobbying | 1 | 2013 | 32 | 0.110 |
Why?
|
Radiotherapy | 1 | 2020 | 1502 | 0.110 |
Why?
|
Office Visits | 2 | 2010 | 595 | 0.110 |
Why?
|
Pancreaticoduodenectomy | 1 | 2017 | 515 | 0.110 |
Why?
|
State Government | 2 | 2009 | 388 | 0.100 |
Why?
|
Hormones | 1 | 2017 | 866 | 0.100 |
Why?
|
Survival Analysis | 7 | 2015 | 10101 | 0.100 |
Why?
|
Terminal Care | 1 | 2004 | 1770 | 0.100 |
Why?
|
Professional Practice | 1 | 2014 | 314 | 0.100 |
Why?
|
Remission Induction | 1 | 2018 | 2410 | 0.100 |
Why?
|
Carcinoma, Renal Cell | 2 | 2019 | 3187 | 0.100 |
Why?
|
Meta-Analysis as Topic | 2 | 2011 | 1363 | 0.100 |
Why?
|
Logistic Models | 6 | 2016 | 13290 | 0.100 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6847 | 0.100 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 3252 | 0.100 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2907 | 0.100 |
Why?
|
Pneumothorax | 1 | 2015 | 393 | 0.100 |
Why?
|
Proportional Hazards Models | 5 | 2014 | 12543 | 0.100 |
Why?
|
Life Expectancy | 2 | 2015 | 1248 | 0.090 |
Why?
|
Private Sector | 1 | 2014 | 396 | 0.090 |
Why?
|
Pharmacy | 1 | 2013 | 92 | 0.090 |
Why?
|
Kidney Neoplasms | 2 | 2019 | 4282 | 0.090 |
Why?
|
Resuscitation Orders | 1 | 2013 | 271 | 0.090 |
Why?
|
Case-Control Studies | 4 | 2024 | 22291 | 0.090 |
Why?
|
Psychotherapy | 1 | 2020 | 1654 | 0.090 |
Why?
|
Hospitals, Community | 1 | 2013 | 365 | 0.090 |
Why?
|
Organoplatinum Compounds | 1 | 2012 | 408 | 0.090 |
Why?
|
Diagnostic Equipment | 1 | 2010 | 11 | 0.090 |
Why?
|
Primary Health Care | 1 | 2007 | 4746 | 0.090 |
Why?
|
False Positive Reactions | 1 | 2012 | 963 | 0.090 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4912 | 0.090 |
Why?
|
Length of Stay | 4 | 2013 | 6498 | 0.090 |
Why?
|
Physician's Role | 1 | 2017 | 925 | 0.080 |
Why?
|
Drainage | 1 | 2015 | 1183 | 0.080 |
Why?
|
Prognosis | 8 | 2024 | 30010 | 0.080 |
Why?
|
Research Report | 1 | 2012 | 369 | 0.080 |
Why?
|
Research Design | 3 | 2018 | 6211 | 0.080 |
Why?
|
Probability | 2 | 2007 | 2479 | 0.080 |
Why?
|
Likelihood Functions | 1 | 2012 | 994 | 0.080 |
Why?
|
DNA | 1 | 2023 | 7214 | 0.080 |
Why?
|
Long-Term Care | 1 | 2013 | 631 | 0.080 |
Why?
|
Critical Care | 2 | 2019 | 2715 | 0.080 |
Why?
|
Choice Behavior | 2 | 2018 | 848 | 0.080 |
Why?
|
Medically Uninsured | 1 | 2014 | 840 | 0.080 |
Why?
|
Esophagectomy | 2 | 2010 | 481 | 0.080 |
Why?
|
Shoulder Joint | 2 | 2006 | 746 | 0.080 |
Why?
|
Residence Characteristics | 2 | 2017 | 2118 | 0.080 |
Why?
|
Health Services | 1 | 2013 | 755 | 0.070 |
Why?
|
Ultrasonography, Mammary | 1 | 2010 | 243 | 0.070 |
Why?
|
Program Evaluation | 2 | 2007 | 2507 | 0.070 |
Why?
|
Geography | 1 | 2010 | 652 | 0.070 |
Why?
|
Laparoscopy | 1 | 2019 | 2041 | 0.070 |
Why?
|
Pain Measurement | 1 | 2018 | 3583 | 0.070 |
Why?
|
Economics, Hospital | 1 | 2010 | 208 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2015 | 6526 | 0.070 |
Why?
|
Financing, Personal | 1 | 2010 | 310 | 0.070 |
Why?
|
Demography | 2 | 2002 | 1641 | 0.070 |
Why?
|
Resource Allocation | 1 | 2010 | 354 | 0.070 |
Why?
|
Immunization Programs | 1 | 2010 | 267 | 0.070 |
Why?
|
Alphapapillomavirus | 1 | 2010 | 219 | 0.070 |
Why?
|
Stomach Neoplasms | 1 | 2017 | 1481 | 0.070 |
Why?
|
Hepatectomy | 1 | 2010 | 588 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2018 | 15948 | 0.070 |
Why?
|
Microsurgery | 1 | 2012 | 800 | 0.070 |
Why?
|
Patient Transfer | 1 | 2013 | 792 | 0.070 |
Why?
|
Information Storage and Retrieval | 2 | 2022 | 830 | 0.060 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 1119 | 0.060 |
Why?
|
Physician Incentive Plans | 1 | 2007 | 165 | 0.060 |
Why?
|
Formularies as Topic | 1 | 2005 | 94 | 0.060 |
Why?
|
Drug Discovery | 1 | 2013 | 1068 | 0.060 |
Why?
|
Counseling | 1 | 2013 | 1554 | 0.060 |
Why?
|
Sex Factors | 3 | 2019 | 10632 | 0.060 |
Why?
|
Observer Variation | 1 | 2011 | 2622 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2862 | 0.060 |
Why?
|
Biomedical Technology | 1 | 2007 | 210 | 0.060 |
Why?
|
Therapeutic Irrigation | 1 | 2005 | 297 | 0.060 |
Why?
|
Consumer Advocacy | 1 | 2005 | 83 | 0.060 |
Why?
|
Drug Combinations | 1 | 2010 | 2089 | 0.060 |
Why?
|
Rectal Neoplasms | 2 | 2003 | 1183 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 6669 | 0.060 |
Why?
|
Multivariate Analysis | 5 | 2013 | 12077 | 0.060 |
Why?
|
Age Factors | 4 | 2016 | 18412 | 0.060 |
Why?
|
Sodium Chloride | 1 | 2005 | 584 | 0.050 |
Why?
|
Austria | 1 | 2024 | 208 | 0.050 |
Why?
|
Models, Biological | 2 | 2011 | 9495 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2008 | 1194 | 0.050 |
Why?
|
Switzerland | 1 | 2024 | 323 | 0.050 |
Why?
|
Pulmonary Embolism | 2 | 2007 | 2599 | 0.050 |
Why?
|
Managed Care Programs | 1 | 2008 | 939 | 0.050 |
Why?
|
Arthroplasty, Replacement | 1 | 2006 | 311 | 0.050 |
Why?
|
Poisson Distribution | 2 | 2015 | 506 | 0.050 |
Why?
|
Pleurodesis | 1 | 2003 | 49 | 0.050 |
Why?
|
Talc | 1 | 2003 | 48 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4860 | 0.050 |
Why?
|
Arthroplasty | 1 | 2005 | 308 | 0.050 |
Why?
|
Specialty Boards | 1 | 2004 | 235 | 0.050 |
Why?
|
Heart Diseases | 1 | 2015 | 2819 | 0.050 |
Why?
|
Thrombectomy | 1 | 2007 | 676 | 0.050 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2010 | 951 | 0.050 |
Why?
|
Maps as Topic | 1 | 2021 | 18 | 0.050 |
Why?
|
Castration | 1 | 2022 | 149 | 0.050 |
Why?
|
Young Adult | 5 | 2018 | 60066 | 0.050 |
Why?
|
Psychometrics | 1 | 2011 | 3063 | 0.050 |
Why?
|
Esophagogastric Junction | 1 | 2004 | 351 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2010 | 10760 | 0.050 |
Why?
|
Tobacco Industry | 1 | 2002 | 138 | 0.050 |
Why?
|
Medical History Taking | 1 | 2004 | 779 | 0.050 |
Why?
|
Program Development | 1 | 2007 | 1300 | 0.040 |
Why?
|
Prejudice | 1 | 2005 | 574 | 0.040 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2024 | 496 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2007 | 1273 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2020 | 39348 | 0.040 |
Why?
|
Health Maintenance Organizations | 1 | 2003 | 657 | 0.040 |
Why?
|
Drugs, Essential | 1 | 2020 | 71 | 0.040 |
Why?
|
Multilevel Analysis | 1 | 2020 | 148 | 0.040 |
Why?
|
Pleural Effusion | 1 | 2003 | 344 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2013 | 20227 | 0.040 |
Why?
|
Ethics, Pharmacy | 1 | 2018 | 6 | 0.040 |
Why?
|
Nephrons | 1 | 2019 | 166 | 0.040 |
Why?
|
Hematopoietic Cell Growth Factors | 1 | 2018 | 98 | 0.040 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2009 | 1417 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 2709 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2003 | 1737 | 0.040 |
Why?
|
Genomics | 1 | 2013 | 5926 | 0.040 |
Why?
|
Pilot Projects | 1 | 2011 | 8741 | 0.040 |
Why?
|
Patients | 1 | 2024 | 908 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2022 | 620 | 0.040 |
Why?
|
Learning | 1 | 2007 | 1759 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2024 | 1542 | 0.030 |
Why?
|
Biomedical Research | 1 | 2012 | 3463 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2018 | 123 | 0.030 |
Why?
|
Patient Compliance | 2 | 2008 | 2697 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2015 | 5889 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2006 | 1668 | 0.030 |
Why?
|
Venous Thrombosis | 1 | 2006 | 1323 | 0.030 |
Why?
|
Quality Assurance, Health Care | 1 | 2007 | 2176 | 0.030 |
Why?
|
Antiemetics | 1 | 2018 | 188 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2024 | 2359 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2020 | 492 | 0.030 |
Why?
|
Colectomy | 2 | 2014 | 696 | 0.030 |
Why?
|
Health Facility Size | 1 | 2014 | 59 | 0.030 |
Why?
|
Prevalence | 2 | 2009 | 15869 | 0.030 |
Why?
|
Role | 1 | 2015 | 176 | 0.030 |
Why?
|
Child | 3 | 2010 | 80917 | 0.030 |
Why?
|
Income | 1 | 2002 | 1878 | 0.030 |
Why?
|
Esophageal Neoplasms | 1 | 2004 | 1668 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2916 | 0.030 |
Why?
|
Stroke | 1 | 2015 | 9755 | 0.030 |
Why?
|
New York | 2 | 2006 | 882 | 0.030 |
Why?
|
Models, Economic | 1 | 2017 | 719 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2830 | 0.030 |
Why?
|
Population Surveillance | 1 | 2003 | 2596 | 0.030 |
Why?
|
Adolescent | 3 | 2015 | 89169 | 0.030 |
Why?
|
Embolism | 1 | 2015 | 401 | 0.020 |
Why?
|
Odds Ratio | 2 | 2020 | 9669 | 0.020 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2015 | 282 | 0.020 |
Why?
|
Psychotic Disorders | 1 | 2006 | 3276 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2002 | 2726 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2227 | 0.020 |
Why?
|
Societies, Medical | 1 | 2003 | 3968 | 0.020 |
Why?
|
Health Promotion | 1 | 2002 | 2210 | 0.020 |
Why?
|
Breast Implantation | 1 | 2013 | 225 | 0.020 |
Why?
|
Rectum | 1 | 2014 | 900 | 0.020 |
Why?
|
Age Distribution | 2 | 2006 | 2873 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2006 | 4423 | 0.020 |
Why?
|
Mutation | 2 | 2024 | 30238 | 0.020 |
Why?
|
Colonoscopy | 1 | 2017 | 1409 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3929 | 0.020 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2010 | 211 | 0.020 |
Why?
|
Thromboembolism | 1 | 2015 | 1004 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2010 | 426 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2004 | 4058 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 934 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2023 | 4530 | 0.020 |
Why?
|
Equipment Design | 1 | 2015 | 3522 | 0.020 |
Why?
|
Health Resources | 1 | 2013 | 950 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3620 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2784 | 0.020 |
Why?
|
Referral and Consultation | 2 | 2010 | 3620 | 0.020 |
Why?
|
Hospital Information Systems | 1 | 2009 | 395 | 0.020 |
Why?
|
Animals | 1 | 2018 | 169246 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2002 | 14783 | 0.020 |
Why?
|
alpha-Tocopherol | 1 | 2006 | 127 | 0.020 |
Why?
|
Atrial Fibrillation | 1 | 2004 | 5176 | 0.020 |
Why?
|
Data Mining | 1 | 2010 | 563 | 0.020 |
Why?
|
beta Carotene | 1 | 2006 | 523 | 0.010 |
Why?
|
Anticarcinogenic Agents | 1 | 2006 | 251 | 0.010 |
Why?
|
Mastectomy | 1 | 2013 | 1861 | 0.010 |
Why?
|
Cardiac Output, Low | 1 | 2004 | 192 | 0.010 |
Why?
|
Surgical Flaps | 1 | 2012 | 1682 | 0.010 |
Why?
|
Hemorrhage | 1 | 2015 | 3467 | 0.010 |
Why?
|
Medical Informatics | 1 | 2010 | 743 | 0.010 |
Why?
|
American Hospital Association | 1 | 2002 | 26 | 0.010 |
Why?
|
Rural Population | 1 | 2013 | 2325 | 0.010 |
Why?
|
Resuscitation | 1 | 2007 | 679 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2017 | 12465 | 0.010 |
Why?
|
Atrial Flutter | 1 | 2004 | 253 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6229 | 0.010 |
Why?
|
Thrombosis | 1 | 2015 | 2957 | 0.010 |
Why?
|
Postoperative Period | 1 | 2006 | 1826 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2006 | 1791 | 0.010 |
Why?
|
Lymph Node Excision | 1 | 2007 | 1271 | 0.010 |
Why?
|
Leadership | 1 | 2010 | 1397 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2006 | 2923 | 0.010 |
Why?
|
Administration, Oral | 1 | 2008 | 4030 | 0.010 |
Why?
|
Urologic Diseases | 1 | 2002 | 246 | 0.010 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2003 | 418 | 0.010 |
Why?
|
Cardiopulmonary Bypass | 1 | 2004 | 1097 | 0.010 |
Why?
|
Epidemiologic Studies | 1 | 2002 | 677 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2004 | 1243 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14729 | 0.010 |
Why?
|
Arteries | 1 | 2003 | 1127 | 0.010 |
Why?
|
Urinary Incontinence | 1 | 2002 | 490 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2004 | 1793 | 0.010 |
Why?
|
Regression Analysis | 1 | 2006 | 6340 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2003 | 1474 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2003 | 2732 | 0.010 |
Why?
|
Syndrome | 1 | 2003 | 3272 | 0.010 |
Why?
|
Radiography | 1 | 2007 | 6983 | 0.010 |
Why?
|
Dyspnea | 1 | 2003 | 1352 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2003 | 1886 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36743 | 0.010 |
Why?
|
Patient Readmission | 1 | 2005 | 3288 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2002 | 2085 | 0.010 |
Why?
|
General Surgery | 1 | 2002 | 1720 | 0.010 |
Why?
|
Clinical Competence | 1 | 2003 | 4858 | 0.000 |
Why?
|
Incidence | 1 | 2006 | 21538 | 0.000 |
Why?
|